Tiratricol
生产企业：Egetis Therapeutics AB
Emcitate (tiratricol) is Egetis Therapeutics' lead drug candidate for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome). It was approved in the EU as the first and only treatment for MCT8 deficiency, and its US New Drug Application is under FDA Priority Review with a PDUFA target action date of September 28, 2026.
Emcitate (tiratricol) is Egetis Therapeutics' lead drug candidate for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome). It was approved in the EU as the first and only treatment for MCT8 deficiency, and its US New Drug Application is under FDA Priority Review with a PDUFA target action date of September 28, 2026.
共 1 项相关疾病
